TD Cowen maintains Ultragenyx Pharmaceutical at Buy, raises price target to $19 from $18

TD Cowen maintained its Buy rating on Ultragenyx Pharmaceutical and raised its price target to $19 from $18, implying a 14.3% upside from the Nov 3 close of $16.63. Recent analyst price targets for the company range from $16 to $22.

Original reporting
Published Nov 4, 2026, 7:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 7:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TD Cowen maintains Ultragenyx Pharmaceutical at Buy, raises price target to $19 from $18 — source image
Decision brief

The 30-second read

$RAREBullishLow
01

Why it matters

The upgrade signals confidence in the company's pipeline, potentially attracting new institutional interest.

02

Market read

A modest analyst upgrade for a micro‑cap biotech, likely to generate limited but positive short‑term price pressure.

03

What to watch

Upcoming clinical trial data or regulatory decisions could dominate price movement more than an analyst target change.

Relevance 5/10Novelty 5/10Timing: today

Background

Ultragenyx is a small‑cap biotech focused on rare diseases; analyst coverage is limited, making any rating change noteworthy.

Company-level read

Ticker impact

$RAREBullishMedium confidence
Context

TD Cowen raised its price target on Ultragenyx Pharmaceutical to $19 from $18, indicating a fresh bullish analyst view.

Expected impact

likely upward pressure as the market digests the higher target

Evidence & confidence

The new target adds ~5.6% upside potential; such upgrades typically generate short‑term buying interest.

Market effects

May marginally benefit other rare‑disease biotech peers as analysts reassess sector valuation.

Limited to US biotech space; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

The target raise is modest and may already be priced in; investors could wait for more substantive catalysts.

Key entities

  • TD Cowen

    Equity research firm that raised the price target.

  • Ultragenyx Pharmaceutical

    Biotech firm developing treatments for rare diseases.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy

Ultragenyx Pharmaceutical Inc (RARE) discontinued two gene therapy programs (GTX-102 and UX701) due to efficacy and trial advancement issues. The company is restructuring, cutting 20% of its workforce. The future of setrusumab for osteogenesis imperfecta is uncertain pending FDA discussions. R&D spending for 2027 is guided at less than $350 million, with a focus on commercial products. The company faces potential competition in the Sanfilippo syndrome type A market.

$RAREHighAI 8/10

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx (RARE) reported Q3 2026 earnings, highlighting FDA approvals for GENGLYCOS and FAYUVI, two new gene therapies. The company also announced setbacks in clinical trials for GTX-102 and UX701, leading to program terminations and workforce reductions. Revenue guidance for 2026 was reaffirmed at $730M-$760M, with profitability expected in 2027. The company aims to reduce expenses by 50% by 2027.